Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationLeasesLong-Term Debt IssuancesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - OtherShares OutstandingShares Outstanding
Ratios

Pliant Therapeutics (PLRX) Shares Outstanding (2019 - 2026)

Pliant Therapeutics has reported Shares Outstanding over the past 8 years, most recently at $61.9 million for Q1 2026.

  • Quarterly Shares Outstanding rose 0.86% to $61.9 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $61.9 million through Mar 2026, up 0.86% year-over-year, with the annual reading at $61.4 million for FY2025, 0.97% up from the prior year.
  • Shares Outstanding was $61.9 million for Q1 2026 at Pliant Therapeutics, up from $61.4 million in the prior quarter.
  • Over five years, Shares Outstanding peaked at $61.9 million in Q1 2026 and troughed at $36.2 million in Q1 2022.
  • The 5-year median for Shares Outstanding is $60.3 million (2024), against an average of $56.4 million.
  • Year-over-year, Shares Outstanding skyrocketed 63.68% in 2023 and then grew 0.86% in 2026.
  • A 5-year view of Shares Outstanding shows it stood at $48.9 million in 2022, then grew by 22.43% to $59.9 million in 2023, then grew by 1.57% to $60.9 million in 2024, then grew by 0.97% to $61.4 million in 2025, then grew by 0.76% to $61.9 million in 2026.
  • Per Business Quant, the three most recent readings for PLRX's Shares Outstanding are $61.9 million (Q1 2026), $61.4 million (Q4 2025), and $61.4 million (Q3 2025).